Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (Nasdaq: DRIO) announced new research in Pain Reports showing that personalized digital therapeutics can effectively reduce back pain. The study analyzed data from 3,610 users over three weeks, revealing significant pain reduction linked to a posture training program enhanced by machine learning. This personalized approach is crucial for optimizing user experiences and promoting ongoing engagement with digital health solutions. Dario aims to empower users through customized interventions, transforming chronic condition management.

DarioHealth Corp. (Nasdaq: DRIO) reported a significant financial turnaround for 2022, with total revenue reaching $27.7 million, marking a 34.8% increase from 2021. The pivot towards a B2B model drove commercial revenue, contributing 59% to total revenue. The operating loss in Q4 2022 dropped to $9 million, a 58% decrease compared to Q4 2021. Cash reserves stood at $49.3 million. Dario achieved over 100 B2B contracts, with total signed value surpassing $65 million. The company anticipates ongoing financial improvement, targeting gross margins of approximately 70% as its multi-condition platform gains traction.

DarioHealth Corp. (NASDAQ: DRIO) will announce its fourth quarter and full year 2022 financial results on March 9, 2023, before the market opens. A conference call and webcast will follow at 8:30 am ET. The call will feature CEO Erez Raphael, President Rick Anderson, and CFO Zvi Ben-David. Participants can join by dialing 1-877-451-6152 for domestic calls or 1-201-389-0879 for international. A replay will be available post-call, with further details accessible via the provided webcast link. DarioHealth specializes in digital therapeutics, focusing on personalized health solutions for chronic conditions.

DarioHealth Corp. (Nasdaq: DRIO) presented two clinical studies at the ATTD 2023 conference, highlighting its digital-first chronic care solution's effectiveness. One study focused on Type 2 diabetes, demonstrating an 18% reduction in blood glucose levels among users engaged with a coach compared to 11% for those without coaching. The second study revealed that older adults experienced a 31% reduction in level 1 hypoglycemic events and a 53% reduction in level 2 events after 6 months of using Dario's platform. These results emphasize the potential of combining human coaching with digital interventions for improved health outcomes.

DarioHealth Corp. (Nasdaq: DRIO) announced its participation in the Cowen 43rd Annual Healthcare Conference, scheduled for March 6-8, 2023, at the Boston Marriott Copley Place. CEO Erez Raphael and President Rick Anderson will engage in a fireside chat on March 6 from 10:30 to 11:00 AM ET. A live webcast will be available at this link and on DarioHealth's Investor Relations website, with a replay accessible for 90 days post-event. DarioHealth specializes in digital therapeutics, addressing chronic conditions through a comprehensive AI-powered platform.

DarioHealth Corp. (Nasdaq: DRIO) announced the appointment of Jon Kaplan as a board member. Kaplan, a Senior Partner at Boston Consulting Group, brings extensive experience in healthcare strategy and transformation. His previous advisory roles at digital health companies enhance his credentials. CEO Erez Raphael expressed confidence in Kaplan's ability to foster strategic relationships for long-term growth. Kaplan highlighted the company's timely shift towards multi-chronic digital healthcare amidst growing demand for scalable solutions. This appointment is seen as pivotal for Dario's future in the digital therapeutics market.

DarioHealth Corp. (Nasdaq: DRIO) has announced a partnership with Dexcom (Nasdaq: DXCM) to integrate continuous glucose monitoring (CGM) data into its digital therapeutics platform. This integration aims to enhance access to Dario's multi-chronic condition management solutions for diabetes patients. With nearly two million users of CGMs, the collaboration is expected to provide personalized support through real-time glucose data. This follows Dario's strategic agreement with Sanofi US, further expanding its digital health ecosystem. The initiative highlights Dario's commitment to enhancing the user experience and meeting market demand for integrated health solutions.

DarioHealth Corp. (NASDAQ: DRIO) announced preliminary unaudited revenue results for 2022, projecting total revenue of $27.5 million, up from $20.5 million in 2021. The shift from Business-to-Consumer (B2C) to Business-to-Business (B2B) is highlighted, with B2B expected to account for 60% of revenue in 2022, a significant increase from 4% in 2021. Operating loss was reduced by over 50% compared to Q4 2021. The company finished 2022 with $49.3 million in cash and begins quarterly payments of $1.5 million on its credit facility with Orbimed in January 2023. Final audited results may differ from preliminary estimates.

DarioHealth Corp. (NASDAQ: DRIO) announced the hiring of Matt Alberico as Senior Vice President of Growth to accelerate growth opportunities in the digital therapeutics market. Alberico previously drove customer growth at Amazon Care, Cigna, and Aetna. His extensive sales strategy experience is expected to help Dario capitalize on increasing market demand for integrated health solutions, following the signing of their 100^th contract. Additionally, Alberico received stock options totaling 100,000 shares at an exercise price of $5.97, vesting over a three-year period.